Current studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are revealing encouraging effects in addressing excess mass and type second-type condition. Preclinical data suggest a unique action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/